Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Posted on by ScienceFather

Prof. Ammu Kutty Radhakrishnan | Cancer Immunology | Best Researcher Award

Prof. Ammu Kutty Radhakrishnan, Monash University Malaysia, Malaysia

 

Prof. Ammu Kutty Radhakrishnan is a distinguished immunologist with a PhD from the University of Cambridge (1994), an MSc in Biochemistry (1990), and a BSc (First Class Honours) from the University of Malaya (1987). Currently, a Professor of Immunology at Monash University Malaysia, she has over 25 years of academic leadership and research experience. Prof. Ammu specializes in immunotherapy and food as medicine research, serving as Head of this research strength. Her career spans significant roles at International Medical University and Oxford. She is a research consultant, active in COVID-19 vaccine efforts, and supervises PhD and MSc students. 🌿🧬📚

 

Publication Profile

Google Scholar

Academic Excellence

Prof. Ammu Kutty Radhakrishnan has an exceptional academic background, with a PhD in Immunology from the University of Cambridge (1994) and degrees in Biochemistry from the University of Malaya. Her education forms a solid foundation for her expertise in immunology and biomedical sciences, contributing to her distinguished career.

Professional Experience

Prof. Radhakrishnan has held key roles, such as Professor at Monash University Malaysia and the International Medical University (IMU). Her leadership in academic programs, such as head of the Food as Medicine Research Strength and chief examiner roles, showcases her commitment to advancing education and research.

Research Contributions

Prof. Radhakrishnan has supervised numerous PhD and Master’s students, guiding 39 doctoral and 20 master’s research projects to completion. Her extensive research supervision experience highlights her dedication to fostering scientific inquiry and innovation. Additionally, her collaborative efforts with industry partners demonstrate her ability to apply research to real-world problems.

Conclusion

Prof. Ammu Kutty Radhakrishnan’s outstanding academic credentials, extensive research supervision, leadership roles, and global health contributions, she is an ideal candidate for the Best Researcher Award. Her work in immunology, biomedicine, and collaboration with industry partners demonstrates her excellence in both academic and applied research, making her a worthy contender for this prestigious recognition.

 

Publication Top Notes  

  • Protective effect of aqueous extract from Spirulina platensis against cell death induced by free radicals (2010) – 292 citations 🧪
  • Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59 (1994) – 259 citations 🧬
  • Rind of the rambutan, Nephelium lappaceum, a potential source of natural antioxidants (2008) – 193 citations 🍇
  • Current concepts of neurodegenerative mechanisms in Alzheimer’s disease (2018) – 176 citations 🧠
  • Bioactive Compounds: Natural Defense Against Cancer? (2019) – 169 citations 🌿
  • Protective mechanisms of flavonoids in Parkinson’s disease (2015) – 162 citations 🧑‍⚕️
  • Tocotrienol research: past into present (2012) – 157 citations 🌰
  • Standardised Mangifera indica extract is an ideal antioxidant (2009) – 149 citations 🥭
  • Nose to brain delivery of rotigotine loaded chitosan nanoparticles in human SH-SY5Y neuroblastoma cells and animal model of Parkinson’s disease (2020) – 128 citations 🚀
  • Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice (2004) – 126 citations 🧫
  • Rutin, a bioflavonoid antioxidant protects rat pheochromocytoma (PC-12) cells against 6-hydroxydopamine (6-OHDA)-induced neurotoxicity (2013) – 124 citations 🧪

 

Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Posted on by ScienceFather

Dr. Gabriel Espinosa Carrasco | Cancer Immunology | Best Researcher Award

Postdoctoral fellow Memorial Sloan Kettering Cancer Center Spain

Gabriel Espinosa Carrasco, Ph.D., is a seasoned immunologist renowned for his research on T cell dysfunction and immunotherapy. With a robust background in biological sciences and immunology, he has contributed significantly to understanding how different immune cell populations interact to combat cancer and autoimmune diseases. His career is marked by his leadership abilities and a strong network of collaborators in the immunology field.

 

Profile

Scopus

Education 🎓

Dr. Espinosa Carrasco holds a Ph.D. in Biological Sciences and Immunology from the University of Montpellier (2011-2016). He earned his Master’s in Advanced Immunology from the University of Barcelona in 2011 and a Bachelor’s degree in Biology from the Autonomous University of Barcelona in 2010.

Experience 🧑‍🔬

Currently, Dr. Espinosa Carrasco is a Post-doctoral Scholar at the Cancer Virotherapy and Immunotherapy Group at Bellvitge Institute for Biomedical Research (IDIBELL). He previously held a postdoctoral position at Memorial Sloan-Kettering Cancer Center, where he worked on projects related to intratumoral immune triads. His Ph.D. research at INSERM Unit 1183 focused on T cell interactions in autoimmune diabetes.

Research Interests 🔬

Dr. Espinosa Carrasco’s research interests lie in the development of new immunotherapies for solid tumors. He focuses on strategies to reverse T cell dysfunction, particularly the role of CD4 and CD8 T cells in tumor immunity. His work includes studying immune cell triads to enhance antitumor responses.

Awards 🏆

Dr. Espinosa Carrasco has received numerous accolades, including the 2024 Best Researcher Award (provisionally), a grant from the Ludwig Center for Basic and Translational Immunology, and the Third Prize Poster Presentation Award at the Tumor Microenvironments Symposium in 2019. He was also an invited seminar speaker at Georgetown University in 2017.

Publications Top Notes📚

Gabriel Espinosa-Carrasco et al. “Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors.” Cancer Cell, 2024. 10.1016/j.ccell.2024.05.025 (Cited by 25 articles).

Mojdeh Shakiba, Gabriel Espinosa-Carrasco et al. “TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion.” J Exp Med, 2022. 10.1084/jem.20201966 (Cited by 40 articles).

Sofia V. Gearty, Gabriel Espinosa-Carrasco et al. “An autoimmune stem-like CD8 T cell population drives type 1 diabetes.” Nature, 2022. 10.1038/s41586-021-04155-4 (Cited by 50 articles).

Gabriel Espinosa-Carrasco et al. “Integrin beta 1 optimizes diabetogenic T cell migration and function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.01156 (Cited by 30 articles).

Gabriel Espinosa-Carrasco et al. “CD4+ T helper cells play a key role in maintaining diabetogenic CD8+ T cell function in the pancreas.” Frontiers in Immunology, 2018. 10.3389/fimmu.2018.02001 (Cited by 35 articles).